Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (371-380 of 627) with videos related to

Pageof 63
Sort By:
European Heart Journal|November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialRichard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Frontiers in Digital Health|July 9, 2025
Retention and characteristics associated with remote questionnaire completion in a general population cohort study: the project baseline health studyMegan K Carroll, Safa Faheem, Jean Bouteiller, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysisChao Li, Jie Yu, Carinna Hockham, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
Journal of Cardiac Failure|April 6, 2024
Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health StudySooyoon Shin, Nathan Kowahl, Taylor Hansen, et al.
Heart (British Cardiac Society)|April 7, 2017
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromesJoakim Alfredsson, Benjamin Neely, Megan L Neely, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Pageof 63

Showing results (371-380 of 627) with videos related to

Sort By:
Pageof 63
European Heart Journal|November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialRichard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Frontiers in Digital Health|July 9, 2025
Retention and characteristics associated with remote questionnaire completion in a general population cohort study: the project baseline health studyMegan K Carroll, Safa Faheem, Jean Bouteiller, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysisChao Li, Jie Yu, Carinna Hockham, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
Journal of Cardiac Failure|April 6, 2024
Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health StudySooyoon Shin, Nathan Kowahl, Taylor Hansen, et al.
Heart (British Cardiac Society)|April 7, 2017
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromesJoakim Alfredsson, Benjamin Neely, Megan L Neely, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Pageof 63